Mesothelin lives on
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
Cell cycle niche seeks clinical validation
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
